BICYCLE THERAPEUTICS PLC
BICYCLE THERAPEUTICS PLC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 29, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
Cash runway is approximately 23.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 29, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 15, 2028 | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Trial Milestone | Phase 2 |
| June 30, 2028 | Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Trial Milestone | Phase 2 |
| August 31, 2028 | Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer | Trial Milestone | Phase 2 |
| March 15, 2029 | A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Trial Milestone | Phase 2 |
| May 30, 2030 | Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product | Trial Milestone | Phase 2 |
Track BCYC alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BCYC in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.